Date: 2012-04-12
Type of information: R&D agreement
Compound: FcRn-overexpressing transgenic mice
Company: ImmunoGenes (Switzerland - Hungary) Amgen (USA)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: ImmunoGenes has initiated a research collaboration with Amgen which is dedicated to explore the opportunities provided by ImmunoGenes’ proprietary FcRn-overexpressing transgenic mice to generate antibodies against “difficult” antigen targets. ImmunoGenes has previously published extensively on the demonstrated ability of the company\'s FcRn transgenic mice to improve antigen presentation and generate increased antibody diversity
Financial terms:
Latest news:
